High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.

ABSTRACT: Dimethyl fumarate (DMF) is an immunomodulatory treatment for multiple sclerosis (MS). Despite its wide clinical use, the mechanisms underlying clinical response are not understood. This study aimed to reveal immune markers of therapeutic response to DMF treatment in MS. For this purpose, we prospectively collected peripheral blood mononuclear cells (PBMCs) from a highly characterized cohort of 44 individuals with MS before and at 12 and 48 wk of DMF treatment. Single cells were profiled using high-dimensional mass cytometry. To capture the heterogeneity of different immune subsets, we adopted a bioinformatic multipanel approach that allowed cell population-cluster assignment of more than 50 different parameters, including lineage and activation markers as well as chemokine receptors and cy

SUBMITTER: Diebold M 

PROVIDER: S-EPMC9351505 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature